COMMUNIQUÉS West-GlobeNewswire

Amwell® to report second quarter 2026 operating results
24/07/2026
BOSTON, July 24, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report second quarter 2026 operating results [...]
Magnendo Secures $18M Series A Financing to Transform Endovascular Access for Stroke Intervention
24/07/2026
MIT spinout to accelerate product development and first-in-human studies of its magnetic robotic navigation platform designed to dramatically improve the speed and reliability of neuro-endovascular procedures NEWTON, [...]
MannKind Announces $50 Million Private Placement
24/07/2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient [...]
BiomX Subsidiary Zorronet Expands European Presence Through Two Strategic Collaborations in Europe
24/07/2026
Collaboration expands Zorronet's AI-powered detection, analysis and response capabilities into agricultural security, theft and critical transportation infrastructure protection NETANYA, Israel, July 24, 2026 (GLOBE [...]
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
24/07/2026
NEW YORK and SYDNEY, July 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative [...]
hear.com Honored as Gold Stevie® Award Winner in 2026 Stevie Awards for Technology Excellence
24/07/2026
Award recognizes Horizon IX hearing aids and Clinic-in-a-Box® tele-audiology for expanding access to hearing care nationwide MIAMI, July 24, 2026 (GLOBE NEWSWIRE) -- hear.com , a global innovator in hearing care, has [...]
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
24/07/2026
Transformative delivery option that may support earlier management of worsening fluid overload with a self-administered option designed for use outside the hospital setting Delivers IV-equivalent diuretic effect through [...]
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
24/07/2026
Company plans to request re-examination following negative CHMP opinion for arimoclomol MAA Zevra continues to support access to arimoclomol for eligible patients through its global Expanded Access Program BOSTON, July [...]
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
24/07/2026
- Positive CHMP opinion supports potential commercialization of obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combination in Europe - - Recommendation based on positive Phase 3 BROADWAY, BROOKLYN, and [...]
Treace to Report Second Quarter 2026 Financial Results on August 7, 2026
24/07/2026
PONTE VEDRA, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Surgery Partners Announces Entry Into Agreement to Sell Ownership Interests in Idaho Falls Facilities to Intermountain Health; Reaffirms Guidance, Excluding Impact of Transaction
24/07/2026
Represents significant milestone in the Company’s ongoing portfolio optimization efforts BRENTWOOD, Tenn., July 24, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a [...]
Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
24/07/2026
SYDNEY, AUSTRALIA, July 24, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced [...]
Dr. Ekta Pandya Named Fellow of Pierre Fauchard Academy, Recognized for Leadership in Dentistry and Children's Oral Health
24/07/2026
Pierre Fauchard Academy Fellow recognized for leadership in dentistry, education, pediatric oral health, and community service Dr. Ekta Pandya, newly named Pierre Fauchard Academy Fellow. NEW PALTZ, N.Y., July 24, 2026 [...]
Ipsen fait le point sur l'essai de Phase III BOLD dans l'atrésie des voies biliaires
24/07/2026
PARIS, FRANCE, 24 JUILLET 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) a annoncé aujourd’hui que l'essai de Phase III BOLD, évaluant Bylvay versus placebo chez des patients atteints d'atrésie des voies biliaires (AVB) ayant [...]
Communiqué de presse: Sanofi annonce sa décision de ne pas soumettre l’amlitélimab dans la dermatite atopique à des évaluations réglementaires mondiales
24/07/2026
Sanofi annonce sa décision de ne pas soumettre l’amlitélimab dans la dermatite atopique à des évaluations réglementaires mondiales Paris, le 24 juillet 2026. Sanofi a annoncé aujourd’hui l’arrêt du développement [...]
Ipsen provides update on Phase III BOLD trial in biliary atresia
24/07/2026
PARIS, FRANCE, 24 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III BOLD trial evaluating Bylvay versus placebo for patients living with biliary atresia (BA) who have already undergone a [...]
Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews
24/07/2026
Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews Paris, July 24, 2026. Sanofi today announced the discontinuation of clinical development of amlitelimab, an OX40- [...]
Codexis Announces Pricing of Public Offering of Common Stock
24/07/2026
REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today [...]
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
24/07/2026
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed [...]

Pages